VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Herpes simplex virus type 1 DNA vaccine encoding GC
Vaccine Information
  • Vaccine Name: Herpes simplex virus type 1 DNA vaccine encoding GC
  • Target Pathogen: Herpes simplex virus type 1 and 2
  • Target Disease: Herpes
  • Vaccine Ontology ID: VO_0011408
  • Type: DNA vaccine
  • Status: Research
  • Antigen: Herpes simplex virus type 1 envelope glycoprotein C
  • UL44 from HSV-1 gene engineering:
    • Type: DNA vaccine construction
    • Description: The HSV-1 KOS gC gene was isolated by PCR. Each gene was initially cloned into a TA cloning vector and then into a eukaryotic plasmic expression vector that uses the cytomegalovirus immediate-early promoter for expression (pRc/CMV for gC) (Nass et al., 1998).
    • Detailed Gene Information: Click Here.
  • DNA vaccine plasmid:
    • DNA vaccine plasmid name:
    • DNA vaccine plasmid VO ID: VO_0000301
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Groups of 5 BALB/cByJ mice received 100-uL injections of purified plasmids into the quadriceps muscles of the hind legs. In most cases, injections were 3 weeks apart; blood samples were taken from the tail vein 1 day before injection or challenge, and approximately equal volumes of blood from individual mice were pooled within a group (Nass et al., 1998).
  • Challenge Protocol: Three weeks after the final injection, mice were challenged ip with 5 x 10^4 pfu of HSV-1 McKrae, which was ~10 LD50S, as determied in BALB/cByJ mice (Nass et al., 1998).
  • Efficacy: Protection against a lethal intraperitoneal challenge of HSV-1 (5 x 10^4 pfu) with gC (UL44) or gE plasmid vaccination could be demonstrated if the inoculating dose of DNA was 250 microg. All mice immunized with vaccinia recombinants expressing either gC or gE survived HSV-1 challenge (Nass et al., 1998).
References
Nass et al., 1998: Nass PH, Elkins KL, Weir JP. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins. The Journal of infectious diseases. 1998; 178(3); 611-617. [PubMed: 9728527].